

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): November 13, 2013

**PROPHASE LABS, INC.**  
(Exact name of Company as specified in its charter)

**Nevada**  
(State or other  
jurisdiction of incorporation)

**0-21617**  
(Commission  
File Number)

**23-2577138**  
(I.R.S. Employer  
Identification No.)

**621 N. Shady Retreat Road**  
**Doylestown, PA**  
(Address of principal executive offices)

**18901**  
(Zip Code)

Company's telephone number, including area code: **(215) 345-0919**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On November 13, 2013, ProPhase Labs, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2013. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>No.</u>	<u>Description</u>
99.1	Press Release dated November 13, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ProPhase Labs, Inc.**

By: /s/ Robert V. Cuddihy, Jr.  
Robert V. Cuddihy, Jr.  
Chief Operating Officer and Chief Financial Officer

Date: November 14, 2013

## EXHIBIT INDEX

No.	Description
99.1	Press Release dated November 13, 2013



**ProPhase Labs Reports Financial Results  
for the Three and Nine Months Ended September 30, 2013**

DOYLESTOWN, Pennsylvania – November 13, 2013. **ProPhase Labs, Inc.** (*NASDAQ: PRPH*, [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com)) today reported its net sales increased \$534,000 to \$5.9 million for the three months ended September 30, 2013 compared to \$5.4 million for the three months ended September 30, 2012. The Company realized net income of \$1.2 million for the three months ended September 30, 2013, or \$0.08 per share, compared to net income of \$1.1 million, or \$0.07 per share, for the three months ended September 30, 2012.

Results for the third quarter of 2013 compared to the third quarter of 2012 principally reflect the net effect of (i) an increase in gross profit of \$418,000, offset by (ii) an increase in research and development costs of \$16,000, (iii) an increase in sales and marketing expenses of \$56,000 and (iv) an increase of \$183,000 in administration costs due principally to an increase in legal and professional costs.

The Company's sales are derived principally from its over-the-counter ("OTC") cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter.

The Company generated net sales for the nine months ended September 30, 2013 of \$15.4 million, an increase of \$2.1 million, or 15.8%, compared to \$13.3 million for the nine months ended September 30, 2012. The Company incurred a net loss for the nine months ended September 30, 2013, of \$193,000, or (\$0.01) per share, compared to a net loss of \$1.5 million, or (\$0.10) per share, for the nine months ended September 30, 2012.

Results for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012 principally reflect the net effect of (i) an increase in net sales of \$2.1 million, (ii) a decrease in research and development costs of \$469,000, offset by (iii) an increase in sales and marketing expense of \$131,000 and (iv) an increase of \$503,000 in administration costs due principally to an increase in legal and professional costs.

The revenue growth we realized for the first nine months of fiscal 2013, as compared to the first nine months of 2012, was in part attributable to the success of our marketing efforts to increase consumer awareness to the benefits of Cold-EEZE<sup>®</sup> Cold Remedy products and generate increased demand for Cold-EEZE<sup>®</sup>. In addition, the timing, stocking and ultimate level of demand of retailer purchases of our OTC cold remedy products are affected by the change in the timing and the comparative severity of the respective cold season as well as the effects of the timing and scope of our marketing and promotional efforts to increase consumer awareness and to influence purchaser decisions.

Ted Karkus, ProPhase Labs' Chairman and CEO stated, "Our strategic focus to grow our top line revenues for our flagship Cold-EEZE<sup>®</sup> brand continues to be realized by our Company. We are achieving growth through increased demand for our Cold-EEZE<sup>®</sup> Cold Remedy line of products. This includes several successful national rollouts of our new premium products which include new delivery forms – lozenges, oral sprays and QuickMelts<sup>®</sup> – to shorten the duration of the common cold. We are efficiently leveraging our marketing dollars and leveraging our distribution platform with our product line expansion initiatives.

We are ultimately impacted by the incidence of upper respiratory illness which is off to a slower start for the 2013-2014 cold season. However, we are well positioned to meet the needs of our retail partners and Cold-EEZE<sup>®</sup> consumers. In July 2013, we began shipping two new additions to our QuickMelts<sup>®</sup> delivery form: Cold-EEZE<sup>®</sup> Cold Remedy Plus Natural Immune Support + Natural Energy and Cold-EEZE<sup>®</sup> Cold Remedy Plus Natural Immune Support. These new products are not new flavors of lozenges but rather Cold-EEZE<sup>®</sup> products in new delivery forms that shorten the duration of the common cold as well as provide additional immune support health benefits. As evidenced in our most recent financial results, we continue to make excellent progress toward our long term strategy of increasing the value of the Cold-EEZE<sup>®</sup> Cold Remedy brand and the value of our Company to the benefit of all shareholders."

### **About ProPhase Labs**

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE<sup>®</sup> Cold Remedy brand as well as other cold relief products. Cold-EEZE<sup>®</sup> zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE<sup>®</sup> customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE<sup>®</sup> lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase's robust over-the-counter distribution channels. For more information visit us at [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com).

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

### **Press Only Contact**

Laura Maxey  
5W Public Relations  
Tel: (212) 452-6400  
[lmaxey@5wpr.com](mailto:lmaxey@5wpr.com)

### **Investor Contact**

Ted Karkus, Chairman and CEO  
ProPhase Labs, Inc.  
(215) 345-0919 x 0

**PROPHASE LABS, INC. & SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(in thousands, except per share amounts)  
(unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
Net sales	\$ 5,949	\$ 5,415	\$ 15,430	\$ 13,328
Cost of sales	2,132	2,016	5,346	4,763
Gross profit	<u>3,817</u>	<u>3,399</u>	<u>10,084</u>	<u>8,565</u>
Operating expenses:				
Sales and marketing	1,091	1,035	5,163	5,032
Administration	1,309	1,126	4,530	4,027
Research and development	181	165	586	1,055
	<u>2,581</u>	<u>2,326</u>	<u>10,279</u>	<u>10,114</u>
Income (loss) from operations	1,236	1,073	(195)	(1,549)
Interest and other income	-	1	2	6
Income (loss) before income taxes	<u>1,236</u>	<u>1,074</u>	<u>(193)</u>	<u>(1,543)</u>
Income tax (benefit) (Note 5)	-	-	-	-
Net income (loss)	<u>\$ 1,236</u>	<u>\$ 1,074</u>	<u>\$ (193)</u>	<u>\$ (1,543)</u>
Basic income (loss) per share:				
Net income (loss)	<u>\$ 0.08</u>	<u>\$ 0.07</u>	<u>\$ (0.01)</u>	<u>\$ (0.10)</u>
Diluted income (loss) per share:				
Net income (loss)	<u>\$ 0.08</u>	<u>\$ 0.07</u>	<u>\$ (0.01)</u>	<u>\$ (0.10)</u>
Weighted average common shares outstanding:				
Basic	<u>15,860</u>	<u>14,836</u>	<u>15,819</u>	<u>14,804</u>
Diluted	<u>16,307</u>	<u>14,981</u>	<u>15,819</u>	<u>14,804</u>

**PROPHASE LABS, INC. & SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEET DATA**  
(in thousands)  
(unaudited)

	September 30, 2013	December 31, 2012
Cash and cash equivalents	\$ 751	\$ 572
Accounts receivable	\$ 4,445	\$ 5,409
Inventory	\$ 3,273	\$ 2,051
Total current assets	\$ 10,579	\$ 10,719
Total assets	\$ 16,667	\$ 16,661
Total current liabilities	\$ 4,741	\$ 4,910
Other long term obligations	\$ 300	\$ 300
Total stockholders' equity	\$ 11,626	\$ 11,451